ArticleFrontiers in public health2025
Divergent trajectories in pancreatic cancer burden among older adults (55+): a GBD 2021 analysis revealing China's dual epidemic of aging and population growth (1990-2045).
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current burden, incidence trends, and future projections of pancreatic cancer in adults worldwide.Journal of global health · 2026Article
- Global surge in pancreatic cancer cases driven by ageing populations and modifiable risks.Journal of global health · 2026Article
- Pancreatic cancer in China: the analysis of cancer mortality and burden in China, 2008-2021.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global population aging trend has intensified concerns regarding pancreatic cancer (PC), a leading cause of cancer-related mortality with a 5-year survival rate of 13%. This study evaluates the global burden, temporal trends, and socioeconomic disparities of PC among individuals aged ≥55 years using the 2021 Global Burden of Disease (GBD) data. Methods: Age-standardized incidence, prevalence, mortality, and disability-adjusted life years (DALYs) were analyzed across 204 countries. Joinpoint regression identified temporal trends (1990-2021), while Bayesian Age-Period-Cohort (BAPC) modeling projected future burden. Socioeconomic disparities were assessed via the Socio-demographic Index (SDI), and risk factor contributions were quantified using decomposition analysis. Results: In 2021, Finland, Germany, and Japan exhibited the highest age-standardized PC prevalence (ASPR: 64.42-66.17 per 100,000 population), contrasting sharply with Mozambique (ASPR: 2.85 per 100,000 population). Mortality peaked in Greenland (age-standardized death rate, ASDR: 81.85 per 100,000 population) and Monaco (ASDR: 71.75 per 100,000 population). Males showed elevated burden across incidence, prevalence, and mortality (peak age: 70-74 years), with global trends persistently rising (average annual percentage change, AAPC >0, 1990-2021). China experienced a transient mortality decline (AAPC = -0.93, 2011-2015), linked to healthcare reforms. High SDI regions (e.g., Japan) faced amplified burdens driven by aging and metabolic risks, while smoking (15.4-28.5% of deaths and years lived with disability, YLDs) and hyperglycemia (37.8% of YLDs in the U.S.) dominated modifiable risks. Projections diverge significantly: China's age-standardized incidence rate (ASIR) burden is projected to increase from 27.96 (95% uncertainty interval, UI: 25.76, 30.16) in 2022 to 36.94 (UI: 0, 79.46) by 2045. In contrast, the global ASIR is expected to decline from 31.07 (UI: 30.06, 32.08) to 27.11 (UI: 8.73, 45.57). Conclusion: Persistent socioeconomic and gender disparities underscore the need for targeted interventions, including tobacco control, glycemic management, and lifestyle modifications. Prioritizing aging populations in high-SDI regions and addressing underreported risks in low-SDI areas are critical for mitigating the growing PC burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.